Home › Major Depressive Disorder › Minnesota
Major Depressive Disorder clinical trials in Minnesota
7 studies for Major Depressive Disorder are looking for participants at sites in Minnesota.
Cities in Minnesota
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Mayo Clinic, Rochester
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Institute for Integrative Therapies, Eden Prairie
- The Remedy Mental Health, Golden Valley
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Minnesota Medical Center Fairview, Minneapolis
- Mayo Clinic, Rochester
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Institute for Integrative Therapies, Eden Prairie
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
- Mayo Clinic, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT06897670Intravenous Ketamine for Treatment-Resistant Depression
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Oct 14, 2025 · NCT06668571Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
- Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis
Recruiting
Ages 18 and older · All sexes · Updated Oct 9, 2025 · NCT05491538From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.